-
Anthony Welch, chairman, said: "We have delivered the rapid revenue growth as promised. We will shortly declare stock dividends, also as promised. We encourage investors to carefully inspect our newest acquisition. We believe the AnuCyte cancer detection system will propel our revenue and profit results well beyond our expectations of only a few months ago. Shareholders should expect frequent updates and rapid progress on the establishment of our diagnostic lab and sales efforts under our new operating arm, Insight Medical Group. We firmly believe the AnuCyte system will quickly obsolesce all other cancer tests currently in existence
يعطيك العافية يا ابو ليان
الشركة طال عمرك في مجال اكتشاف السرطان
و قد اعلنت عن مداخيل احسن بكثير من مداخيل العام الماضي
الفوليوم الى الان يوحي بعدم التفاعل مع الاخبار
و يبقى السهم تحت النظر يا بو ليان
-